BiotechTube
SRTD biotech

SRTD biotech

Hamburg, Germany· Est.
srtd-biotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.5M

Overview

SRTD Biotech is a private, preclinical-stage biotech developing a proprietary 'RNA pro-drug' platform termed seRNA (selectively expressed RNA). The technology merges RNA interference for cell-specific targeting with mRNA for effector molecule expression, delivered via proprietary lipid nanoparticles (fLNPs). The company's initial pipeline focuses on oncology (HCC, glioblastoma, lung cancer), with plans to expand into viral and autoimmune diseases, aiming to overcome the off-target side effects common to many existing therapies.

OncologyAutoimmune DiseasesViral Diseases

Technology Platform

Selectively Expressed RNA (seRNA) platform: A modular RNA pro-drug technology that combines RNA interference for cell-specific transcript targeting with mRNA for localized expression of therapeutic effector proteins, delivered via proprietary formulated lipid nanoparticles (fLNPs) for organ-specific delivery.

Funding History

2
Total raised:$3.5M
Seed$3M
Grant$500K

Opportunities

The modular seRNA platform offers a potentially universal approach to treat a wide range of diseases by simply swapping targeting and effector modules, enabling rapid pipeline expansion.
The high unmet need in lead oncology indications (HCC, glioblastoma) and the validated RNA therapeutics market create a significant commercial opportunity for a successful product.

Risk Factors

The novel and unproven seRNA mechanism carries high preclinical and clinical development risk.
As a pre-revenue company, SRTD is dependent on raising significant capital to advance its pipeline, facing substantial financial risk.
Intense competition in the RNA therapeutics space from larger, well-resourced companies poses a major competitive threat.

Competitive Landscape

SRTD operates in the highly competitive RNA therapeutics arena, competing with established mRNA companies (e.g., Moderna, BioNTech), RNAi specialists (e.g., Alnylam, Arrowhead), and numerous biotechs developing targeted delivery technologies. Its differentiation hinges on proving its seRNA activation switch offers superior cell specificity and safety compared to conventional targeted approaches.

More companies in RNA Therapeutics (non-mRNA) →More companies in Germany →